- Conditions
- Rhinitis, Seasonal, Allergic
- Interventions
- PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg, PSE 120 mg, CM 8 mg, Atropine 0.24 mg
- Drug
- Lead sponsor
- Magna Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 4
- States / cities
- Stockbridge, Georgia • Louisville, Kentucky • Charleston, South Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Accomodation, Biofeedback Training, Myopia
- Interventions
- Auditory biofeedback traing
- Behavioral
- Lead sponsor
- State University of New York College of Optometry
- Other
- Eligibility
- 8 Years to 15 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Long Beach, New York
- Conditions
- Mild Cognitive Impairment
- Interventions
- Donepezil, Atropine
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myopia
- Interventions
- Atropine Ophthalmic, MiSight 1-day disposable contact lenses
- Drug · Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 21 Years to 30 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Respiratory Distress Syndrome, Newborn
- Interventions
- Endotracheal intubation, Laryngeal mask airway, remifentanil
- Device · Drug
- Lead sponsor
- Albany Medical College
- Other
- Eligibility
- 2 Hours to 48 Hours
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Toxic Effect of Organophosphate and Carbamate Insecticides
- Interventions
- Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
- Drug
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Myopia
- Interventions
- Atropine, Placebo Eyedrops
- Drug · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Boise, Idaho + 10 more
- Conditions
- Diastolic Dysfunction
- Interventions
- Dobutamine stress echo (DSE), Atropine bolus
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Irinotecan
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Albuquerque, New Mexico • Santa Fe, New Mexico
- Conditions
- Sleep Apnea, Obstructive
- Interventions
- Dexmedetomidine, Propofol
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 12 Months to 25 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Myopia, Progressive
- Interventions
- OT-101 Ophthalmic Solution, Vehicle
- Drug
- Lead sponsor
- Ocumension (Hong Kong) Limited
- Other
- Eligibility
- 3 Years to 15 Years
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 15
- States / cities
- Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more
- Conditions
- Pain
- Interventions
- Diclofenac and Atropine combination drug, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COPD, Sepsis, Shock
- Interventions
- Levalbuterol, Albuterol
- Drug
- Lead sponsor
- Fahim Khorfan, MD
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Grand Blanc, Michigan
- Conditions
- Cerebral Palsy, Sialorrhea
- Interventions
- Atropine sulfate gel (0.01%)
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- tiotropium, Combivent (Ipratropium/Albuterol)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
- Conditions
- Asthma, Depression, Childhood Asthma
- Interventions
- Ipratropium Bromide
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
- Interventions
- Donepezil
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumors, Lymphoma
- Interventions
- LMP744, Ondansetron, Olanzapine, Lorazepam, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Loperamide, Diphenhydramine, Steroid, Epinephrine
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, Inflammatory
- Interventions
- Tirzepatide, Loperamide, Diphenoxylate/Atropine
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Rochester, Minnesota • St Louis, Missouri + 2 more
- Conditions
- HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Neratinib, Trastuzumab, Loperamide, Crofelemer, Diphenoxylate/Atropine
- Drug · Biological
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Post Bariatricsurgery, Hypoglycemia
- Interventions
- Exendin-(9-39), Atropine, GLP-1 and GIP
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Myopia, Progressive
- Interventions
- Atropine Sulfate
- Drug
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- Not listed
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- COPD, COPD Exacerbation
- Interventions
- Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
- Device · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Rhegmatogenous Retinal Detachment
- Interventions
- Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
- Procedure · Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts